Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Devyser Diagnostics, Audiocast, Q3'25

By Inderes11/5/2025, 8:00 AM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jan Wahlström
00:01 - 05:47

Good day and welcome to the Devyser Q3 2025 Earnings Call. I'm Jan Wahlström. I'm the new CEO of Devyser as of August 2025. And I would like to thank everyone for joining our call today. On the call today, we have, in addition to myself, our CFO Sabina Berlin and our CCO, Theis Kipling. I will start with a short summary of our quarterly results, and then recap our recent activities that resulted in improved efficiency overall for the organization. I will then give an update on the recent product launches and present some additional highlights from the quarter, before handing over to Sabina. For a more detailed review of our financial results in Q2, Q3, and then to Theis for an update on our recent commercial activities. As I said, my name is Jan Wahlström. I've now completed my first quarter as the CEO of Devyser. It is a privilege to have joined such a talented team of colleagues, a team that over the years has delivered fantastic products in a very important field, doing so with stellar growth. I have a background from several similar companies where I have delivered strong growth both on the top line and even more so on profitability by ensuring a clear focus, continuous improvements in how we work, and at the same time staying top in class in our offering. I'm looking forward to this journey at Devyser. Looking into the third quarter highlights, this quarter shows that we're turning the company around onto a path to profitability. We have another record quarter based on revenue, with 56 million in sales, representing a growth in local currency of 20% and 16% in Swedish crowns compared to Q3 last year. Q3 is normally the slowest quarter of the year. We believe that 20% growth is a strong result. We're most proud. In the quarter, we achieved an EBIT of positive 1.3 million crowns compared to -22 million last year. We currently have a cash position of 85 million. If I then look at the year-to-date financials, the reorganization we initiated in February has given us a strong structure that we have been able to capitalize on in the second and third quarters. To date, we are at EBIT minus eight compared to minus 59 in the same period last year. So, the development is really strong. Sales year-to-date is 179 million, representing a growth of 17%. We are turning the company towards profitability during the second half. We are focusing on delivering continued strong growth supported by the launch of new products. We launched Genomic Blood Typing HLA Loss just before the quarter started, and now we have also launched the IVDR product for CFTR. We continue to generate a strong product roadmap for the coming years that quantifies the opportunities and meets the needs communicated by our customers. We have implemented several internal processes to improve our organizational efficiency. This is something that I've done several times before in other companies, and I see that we have a good opportunity to improve our efficiency and profitability going forward. The product launches we had were mainly done in Q2. As I mentioned, in Q3 we have had fewer updates on Genomic Blood Typing and HLA Loss, which is normal for us. But yesterday, as you might have seen, we launched CFTR IVDR. That is part of our focus on moving products from research use only and IVDD to IVDR, something that Theis will talk more about later on in the call. This is putting us in a better competitive position in most markets, but especially in Europe. More feedback on other topics. I would like to highlight a couple of activities from the quarter. Work continues in the lab and on the ongoing MolDx evaluation for a post-transplant test in the US. MolDx provided feedback on our application at the end of October and requested additional supporting data, which we are currently reviewing. At the same time, we continue to work on our FDA project in transplantation. Over the quarter, we have been able to register more labs that are participating in the ongoing study. This marks an important step in the process for us, as we now have all the labs that we need for the study. With that, I would like to hand over to Sabina to share more details on our financial results for the third quarter. Sabina.

Sabina Berlin
05:49 - 09:02

Thank you. John. I'll continue with the summary here of the financials for Q3. Revenue for the period July to September came in at 56.4 million, compared to 48.7 million in the same quarter of last year. This amounts, as Jan mentioned, to quarter-on-quarter growth of close to 16%, equaling 19% in local currency. Over the past two years, we have noticed increased variability between separate quarters, with softer third quarters due to order patterns and the impact of the summer months. With a stable underlying trend, we will delve more into market dynamics during the quarter and also going forward. There will always be fluctuations between individual quarters, with two very strong quarters and two softer quarters over the past 12 months. We still see a stable rolling 12-month curve that continues along the same trend as in previous years. The Americas continue to show very strong growth in Q3 with an 87% increase quarter over quarter, although still starting from small numbers, with the main growth coming from lab and US kit sales. Our EMEA region tends to be slower in the months of July and August due to vacation order patterns, but did pick up in September as usual. Q3 saw direct sales showing the strongest growth out of our two sales channels, confirming a healthy growth trajectory. Distributor sales were very strong in Q2, with a major contribution from the transplantation agreement with Thermo Fisher Scientific, and Q3 had strong distributor sales last year. Both these factors led to a softer quarterly growth on the distributor side this year, as no major orders from Thermo came in during Q3. But we are also expecting this channel to pick up soon again. This will cover more details also about the channel markets shortly. And gross margin came in at 75% during the quarter, better than last year, with a year-to-date of 81%, well above our financial target. Our EBIT for the quarter of 1.3 million is positive for the second quarter in a row, although actual positive amounts are still just above zero. It clearly shows the effect of the savings program implemented earlier this year and confirms our ability to move forward with a long-term, sustainable, cash flow positive business. We closed the quarter with 85 million in cash, and the cash flow for the quarter of -15.2 million is mainly impacted by capitalized R&D work, as cash flow from operating activities was only -0.5 million. We strongly believe that our investments in new products will continue to pay off and support future growth in both the transplantation field and the hereditary disease business. I feel confident that our performance will take us to cash flow positive within the foreseeable future. And with that, I hand over to Theis.

Theis Kipling
09:03 - 16:15

Thank you, Sabina and Jan, and good morning from Stockholm. I'm pleased to share several promising highlights from Q3, which was another strong quarter where we continued to deliver in our respective markets. Q3 was indeed a good quarter considering the lower number of orders from Thermo Fisher, which was just as expected. The quarter was focused on launching our new products within Genomic Blood Typing as well as HLA Loss. We attended one of the main events of the year in transplantation, which generated many promising leads for HLA Loss, often used as a reflex test for Chimerism, and hence beneficial for the overall demand for our transplantation portfolio. We have now managed to triple the number of customer leads compared to last year, which reflects our focus on maximizing the return on our marketing investments. We expect this growth to continue as we become more recognized and trusted as a company and laboratory partner, combined with how we focus our efforts. This is an important underlying component for the growth of new customers. Our growth in North America continues as we are consistently onboarding new customers that, once they move into clinical routine, will further accelerate the momentum. The growth here in Europe is also continuing as per plan. As Jan mentioned already, we have some very strong fundamentals at Devyser. We have a wide, strong, and workflow-efficient product portfolio. We have a strong regulatory capacity, and we are leading in Europe when it comes to IVDR. This new regulation represents a structural change to our market, and I'm proud to see how well we have it under control. We have multiple strong growth drivers, including transplantation, across the largest markets of the world, spearheaded by the US with our CLIA lab and our FDA program. And we are partnering with some of the largest and strongest companies within our field, including Thermo Fisher and Illumina. Moving to an update on our partnership with Thermo Fisher. Q3 was, as expected, a slower quarter due to the strong Q2 performance, which we expect to see again in Q4, following the previous pattern. During the quarter, we attended one of the main events within transplantation, the ASHI Conference in Orlando, US, which went exceptionally well. We had a well-attended customer and collaboration event with lots of interest, and several demonstrations are already scheduled as a follow-up. Our transplantation business continues to shape our company and will remain a significant potential and strong growth driver for the company. Future. Looking into North America. We had a strong quarter and actually achieved tenfold revenue growth over the same period last year, excluding transplantation, driven by Cyted and the new accounts coming on board. While it's still early days, we are seeing RHD in the US driving a lot of the growth already, which is only expected to accelerate once Quest Diagnostics gets this product ramped up within their business. The collaboration with Cyted is developing well and is expected to grow further during the coming years on the back of their successful capital raise during this past quarter. Next up is getting Canadian Blood Services in Canada to start their clinical routine work with RHD alongside the University of North Carolina in the US with our test for cystic fibrosis. Moving on to Europe, I'm pleased to share that Italy had a very strong quarter with 19% growth. Italy had a softer quarter, as you may recall, in Q2, but truly bounced back completely during this quarter. As expected, the fundamentals in this important market are strong, and we continue to succeed in upselling to existing accounts while still bringing in new accounts. Our new one-stop-shop strategy is working well, and as mentioned, we are onboarding many new accounts while successfully increasing the number of products sold to existing customers. As mentioned in some recent analyst reports, we are working on an exciting tender opportunity with the University of Leuven focused on CFTR NGS, which was the product that received IVDR certification yesterday. This tender is still early on, hence we honestly don't know if we will win it, but it would be a significant addition to our business if we do. An incremental and sizable addition to our business within the Benelux market. Jan and I attended a global diagnostics conference in London in early October, where it was clear once again that many companies, both large and small, are struggling with meeting the increased standards in Europe when it comes to IVDR. This is something that we, as a company, are pursuing vigorously as a strategic initiative, as we believe it will be a solid growth driver for Devyser in the years to come. To close the commercial update, I would like to reconfirm that we have a very strong and healthy set of fundamentals across the business that continue to serve us well, and I'm excited with the early momentum that we are already seeing here in Q4.

Jan Wahlström
16:17 - 17:04

Thank you. Thank you, Sabina. We have now delivered another quarter with positive EBIT, the second in a row, and a much improved result compared to last year's Q3. We continue the path forward towards our long-term goals, leveraging our investments in new products and collaborations with big companies in our industry. At the same time, we now have a clear theme towards continuous improvement and increased profitability, while maintaining strong top-line growth. We are on a clear path towards cash flow, positive results, and also towards our long-term goals. With that, I would like to open up to questions.

Operator
17:06 - 17:23

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
17:25 - 18:10

Thank you very much and good morning. If we can start with distributor sales, they are down quite substantially year over year, despite last Q3 not being a massive quarter for you. Are you still confident in your previous comments on growth in H2, with sales in H2 being higher than in H1? And how should we look at the ordering pattern from Thermo Fisher for the end of the year, and can you provide some type of granularity? How much Quest Laboratories, as requested, contributed here in Q4? That would be my first question, please.

Theis Kipling
18:13 - 19:08

Would you like me to start? Let me start by addressing the issue of distributive sales being overall slow. I mean, as we have explained, the contribution of Thermo Fisher is very significant within the distributor channel. And they did deliver a very strong Q2. We saw a very strong Q4. As a consequence, Q3 is slower, but we do expect that, as per the pattern, it will bounce back in Q4 because there's nothing to suggest that any demand has changed. On the contrary, we have reaffirmed that this is a growing business. So, we have a very close dialogue with Thermo Fisher. So we feel confident that will continue. We also think and believe that H2 will be stronger than H1. That's just the nature of how the business is growing.

Ulrich Trattner
19:11 - 19:18

Great. And on Quest's contribution for Q3.

Theis Kipling
19:19 - 19:52

Unfortunately, I am very much restricted in what I can share in that sense. When we look at the US-specific market, we do see that it is quite a substantial contributor to the growth that we are witnessing, which was very significant in the quarter. And, year to date, we are up by approximately three times compared to the last year on a year-to-date basis. And this is already in Q3, driven largely by the acceleration by Quest Diagnostics. But I cannot go into more specifics.

Ulrich Trattner
19:54 - 20:23

Fair enough. And on MolDx, you've talked about this before as a big inflection point, especially for your post-transplant monitoring product. As you stated, they reported that additional data was requested, can you provide more information on what that implies? And then in terms of what that implies regarding timelines, is it still expected to be in place with reimbursement before year-end, or what should we expect?

Jan Wahlström
20:25 - 20:39

We just received the feedback from them. Just recently. And we're evaluating and looking into that. And we need to come back with a more exact result on that evaluation.

Ulrich Trattner
20:41 - 20:53

And is it possible to give us some type of hint about what type of data they are requesting? Is it additional clinical data? Is it sort of health economic data? What type of data are they requesting?

Jan Wahlström
20:54 - 20:57

It is additional clinical data that they're requesting.

Ulrich Trattner
20:59 - 21:38

Okay. Regarding direct sales, there have been strong developments this quarter. And you talk about the slow summer months, what is the functionality behind the growth? Is that part of an expanding product portfolio, or is it just that you're gaining more traction in the market? And I assume, given that you stated you have good traction in the market and good commercial progress, that one should assume that it should be growing sequentially into Q4 from slower summer months, as you stated.

Theis Kipling
21:41 - 22:29

Yeah, I can add, I mean, that's really what we're about as a company. We have two pathways through which we sell our products. One is within the clinical genetic labs and the other one is within transplantation. And we are, as a company, very strong in continuously launching new products. That, in itself, will drive additional growth. And then, as we mentioned, within the existing portfolio that we already have, we are successfully bringing in quite a substantial number of new accounts. And with all of the existing accounts, we are increasing the share of wallet. So that is essentially driving a lot of the growth, and it's a fundamental growth driver for the company. And then you have these core enablers, as you referred to before, with the transplantation on top.

Ulrich Trattner
22:32 - 23:04

What type of data are they requesting? Uh, and last question on my end, The Canadian Blood Service, which is now expected to go live early next year and Hema Quebec by the second half of next year. These are quite substantial tenders you've been awarded. Is it possible for you to quantify what this means? And given that these are screening programs, would this imply that you carry a lower gross margin on these products?

Theis Kipling
23:05 - 23:45

On the latter part, I can say clearly. No. So there's no dilution in gross margins in any way. Uh, it's true. These are already a few years old since we initially got them awarded. So, they've taken some time before they go live. With that said, I will refrain from going deeper into the volume and the potential topline effects. These will be incremental businesses that we expect to be able to cover the majority of the Canadian market with our RHD testing. And that will, however you look at it, be a very promising opportunity.

Ulrich Trattner
23:48 - 24:13

And just a quick follow-up, I'll look back into the queue. Is this a sort of gradual step up that you were expecting, or is it fully live from January 1st and then Quebec by Q3, or is it something that will progress sequentially throughout the year and have full effects on your end by 2027?

Theis Kipling
24:13 - 25:02

Yes. I mean, as much as I would wish any account would go from 0 to 100 in a week, unfortunately, despite my best wishes, it doesn't happen. So it will be a gradual increase as they get this test fully implemented across the country. The same is what we're seeing as we look at Quest Diagnostics across the US. It just takes time. It needs to reach out throughout the full commercial organization, address all customers before you see a true ramp-up and consistent demand. It just takes time, and when we will see the full commercialization effects is going to be guesswork. So I'm going to refrain from commenting on that. But you should expect that there will be a ramp.

Ulrich Trattner
25:03 - 25:23

And just a quick follow-up, I'll look back into the queue: is this a sort of gradual step-up that you were expecting, or is it fully live from January 1st and then Quebec by Q3, or will it progress sequentially throughout the year and be fully effective on your end by 2027? And just last question to Sabina or the rest of you as well. 85 million in cash. End of the quarter. Do you still And I've asked this before, do you still feel comfortable with the current cash level to run your operations as you wish in the coming years?

Sabina Berlin
25:24 - 25:28

Yes, we do. Short and concise and very truthful.

Ulrich Trattner
25:31 - 25:36

All right. Well, thanks. Alright, Jan, and Sabina. I will get back into the queue.

Sabina Berlin
25:37 - 25:37

And just a quick follow-up, and I'll look back into the question, is this a sort of gradual step-up that you were expecting, or is it fully live from January 1st and then in Quebec by Q3, or will it progress sequentially throughout the year with the full effects on your end by 2027?

Operator
25:42 - 25:46

The next question comes from Phillip Wiberg from Pareto Securities. Please go ahead.

Phillip Wiberg
25:48 - 26:08

Hi. Good morning. So firstly, just a follow-up on the prior questions around reimbursement here. So I get that you cannot say too much right now. But when do you expect to be able to come back with some more information regarding the feedback and the new timeline? Is it the end of this year or is it more towards the next year?

Jan Wahlström
26:09 - 26:14

We expect to be able to come back with some feedback before the end of this year.

Phillip Wiberg
26:16 - 26:35

Okay. Perfect. Thanks. And then just a question on the financials here. First, let's discuss the gross margin. The gross margin is down at 75% due to quite high COGS. Could you elaborate a little bit on what the impact is? So was there anything specifically in the quarter?

Jan Wahlström
26:40 - 26:47

So what's the question on why the gross margin was lower than before? Do you understand?

Phillip Wiberg
26:47 - 26:58

Yeah. Well, the. Yeah, exactly. So the COGS were quite high, and even though sales weren't as high as in Q2, for instance. Is it the end of this year or is it more towards the next year? Was there anything special about the impact of this?

Jan Wahlström
26:58 - 27:32

Is it the end of this year or is it more towards the next year? The way that we are set up when it comes to COGS is that we have some fixed costs that go into it. As the quarter is lower than, for example, Q2, that reflects badly on the gross margin. So if you look at the gross margin and compare it to Q3 last year, you do see a definite improvement. And so for us, nothing has changed in the product mix or the pricing and margins that we have, so this is what's normal in that sense.

Phillip Wiberg
27:35 - 27:45

Is it the end of this year or is it more towards the next year? Yeah, I'm just thinking. Last year was quite heavily impacted by the move to new premises, which should now be out of the system. So, it seems quite extensive. The effect here in this quarter.

Jan Wahlström
27:45 - 28:01

I think that the Cogs were not affected last year, so that's okay. So it was somewhat affected in that sense. I would still say that the margin we have now is what we would have expected in Q3 given the sales volume.

Phillip Wiberg
28:03 - 28:21

Okay. Perfect. Thank you. And then another one on the OpEx here. So is it only an effect of the cost-saving measures that you've implemented, or was there anything else that affected it this quarter? So, you know, I'm just trying to understand what to expect going forward. This is a new baseline. So to say.

Jan Wahlström
28:22 - 28:35

I would say there was nothing specific this quarter. It was actually very much driven by the cost savings done in the spring and the continuous work on making sure to keep the costs at a good level.

Phillip Wiberg
28:38 - 28:58

Okay, good. And last question from me here. So you know the financial target of reaching 30% growth. It looks quite tough this year. So, with the delay of the reimbursement in the lab, how confident are you about reaching that during 2026? Or do you feel it's a bit too high, or what should we expect?

Jan Wahlström
28:59 - 29:27

When we look at the different targets? If you take the growth target and look over a longer period of time, I think that we are actually about 30% growth. And so, we see that we are in line with that. And when it comes to the gross margin, we're also above 80% on average. The third target that we have in terms of profitability is something we are moving towards, and it remains our target to reach.

Phillip Wiberg
29:30 - 29:39

Okay, but is there anything that changes around your expectations for the next year? Now, with the delay in the reimbursement in the lab, is there any change?

Jan Wahlström
29:41 - 29:43

No, there are no changes to that.

Phillip Wiberg
29:44 - 29:47

Okay. Okay, good. That's all from me. But I would still say that the margin that we have now is what we would have expected in Q3 given the sales volume.

Operator
29:52 - 29:56

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
29:58 - 30:23

Yes. Hi. And thank you for taking my questions. So starting off in the direct sales channel, I believe you have quite a significant share of tender-based sales here. So then I wonder if. Yeah, you should have quite good visibility into this part of the sales channel. So I just wonder if you can give some flavor on the outlook for this towards the end of the year and into 2026.

Jan Wahlström
30:25 - 30:32

And no, we can't do that. We don't give any outlooks looking forward. Sorry about that.

Ludvig Lundgren
30:34 - 31:05

All right, fair enough. And then jumping to distributed sales instead. You highlight that there were no major orders from Thermo Fisher in Q3, partly explaining this year-over-year decrease. But, yeah. So basically, Thermo Fisher has been working down its inventory during this quarter. Do you have any visibility on their current use of kits? And if this has increased year over year, looking into Q4, if you receive an order from them, will it be larger than last year?

Jan Wahlström
31:06 - 31:24

We cannot comment on the size of the orders from Thermo, and we don't have visibility into the inventory of what they have. What we do know is that they have good traction on the products and that they're delivering well in the market. I don't know if you want to comment more, Theis.

Theis Kipling
31:24 - 32:25

Exactly, exactly that. We know that they are successfully onboarding several new accounts across North America, Europe, and even in international markets. It's a very healthy business. And maybe just a side comment to your previous question, since we are very much a tender-driven business. You know, a lot of our business is tied up in long-term contracts, and that means it's super sticky, right? We have very limited, if any, losses in any way across customers. On the customer side of things, you can look at our previous performance and also Q3 and view that as a reflection of how our base business is going. And if you ask me, I think we are representing a very healthy underlying base business based on some very strong fundamentals.

Ludvig Lundgren
32:29 - 32:54

Please go ahead. Great. Thanks. So just a follow-up on the Thermo. The adjustment or the Thermo Fisher order, more specifically the Thermo Fisher order from last year. So just set some reasonable expectations for Q4. Were there any initial volumes that you received that you probably won't see this year? Or was that only products that have been worked on since then?

Jan Wahlström
32:56 - 33:09

So as we said, we don't have visibility into the inventory of Thermo. And we cannot comment on the size of orders that we get from them going forward.

Ludvig Lundgren
33:12 - 33:44

Okay. Thank you. And then just a final one on cost. So diving a bit more specifically into the SG&A part, which is a significant part of cost in the P&L. So, 26 million in selling expenses and 11 million in administrative costs are partly affected by, you know. These cost savings. But I guess there's also some seasonal component in here. So just as we head into Q4, is it fair to expect both of these to increase a bit? Q over Q, or should we extrapolate this level ahead?

Sabina Berlin
33:46 - 34:17

I mean, as Jan said, we're very careful about guiding going forward. But yes, any company running IFRS does have a seasonal component over the summer as the vacation period has a positive impact on opex. The main difference, if you compare to previous years, is the effects of the savings program. So there is a healthy run rate underlying the numbers to take forward into the coming quarters as well.

Ludvig Lundgren
34:20 - 34:23

Okay. Perfect. Thank you very much. I'll jump back into the queue.

Theis Kipling
34:28 - 34:29

And maybe the.

Operator
34:29 - 34:33

The next question comes from Oscar Bergman from Redeye. Please go ahead.

Oscar Bergman
34:35 - 35:03

Hi, guys. I have a few crumbs left. On the questions side, I'm just wondering if we can start off by continuing with the questions regarding opex, because you have made some really significant changes compared to Q1 this year. And I'm just wondering what more can you do here in the organization to reduce costs? Should we see this as fully implemented by now?

Jan Wahlström
35:04 - 35:33

I believe a very good job was done at the beginning of the year, Oscar. However, I still believe that we can continue to work on these improvements, make sure we're more efficient in what we do, and work on improving all our comparable numbers in that area. It's not something that is done in a quarter, but it's something that is going to be worked on over the next one to two years.

Oscar Bergman
35:34 - 35:46

I got a few crumbles left. And then, considering a more focused approach to the US market, how should we expect a US organizational build-up to reflect operating expenses going into 2026?

Jan Wahlström
35:48 - 36:16

Looking at the way that our business is set up in the US right now, we don't foresee a huge build-up in the US organization today. We work with different partners, as you know, in various areas, and we will continue to do that. So, it's going to be business in the US the same way as we do with our commercial organization in Europe and in Asia. So it's not different in any way.

Oscar Bergman
36:18 - 36:40

And I remember that a few years ago there was a lot more focus on converting distributor markets to direct sales markets. Just wondering if you can provide some commentary on that. And if perhaps the direct sales in Q3 is boosted by any type of distributor to direct sales conversion.

Theis Kipling
36:41 - 38:51

I can take that one. The last part of the question. No, there are no effects from making any changes to the way we approach the market. There have been no impacts in the quarter, and it's not really something we are currently working on as a growth driver for us. We are very focused on doubling down on the markets where we are direct currently. And, as I've mentioned before, we do see that it's going really, really well. We will see here starting January that we in Spain are moving fully direct. We have completed the carve-out of customers from the distributor and will be managing and serving them from our own operations, which is very exciting because that market, if you look at it, is even larger than Italy. So I'm really hopeful that we can achieve a lot of positive outcomes, particularly in Spain. I've set the same for Benelux. You heard about the tender that we’re working on. I think you were the one who picked up on that one initially as well. Nordics, you know, there's a lot of positive underlying momentum that is building. And just on the OpEx side, G&A focus, I think with the arrival of Jan, that marks a new chapter. If you look at what John has done in the prior companies, he has sustained and built growth while driving a very disciplined organization that focuses on incremental EBIT margin building. And I think that's why we are excited about what we are about to see there. And in the commercial organization, we still have quite a bit of scalability. So we're not, as John said, expecting any buildup.

Oscar Bergman
38:52 - 39:15

All right. Thank you very much. A very interesting aspect of converting distributor markets to direct markets is that it can eliminate the distributor margin, allowing you to increase your prices. Is this a fair assumption then, that the selling prices in Spain should be increasing quite a lot in the short term? Or how do you expect to proceed with those changes?

Theis Kipling
39:15 - 39:16

Do you know how to proceed with those changes?

Oscar Bergman
39:16 - 39:17

Do you plan to implement those changes?

Theis Kipling
39:17 - 39:34

Not assumptions. But we will. We will, while it's now us managing those customers, there is the upselling opportunity. Having that direct customer relationship will drive a lot of the incremental growth in that market. But no, there won't be any effects on the end user pricing.

Oscar Bergman
39:35 - 39:54

All right. In Italy, you reported 19% sales growth. Just wondering if you can provide some commentary on how Italy has progressed in Q4. And if we should look at the high growth in Italy as sort of a one-off occurrence in Q3.

Theis Kipling
39:56 - 40:07

Looking at Italy, they have historically been driving high single and modest double-digit growth. And very consistently. And that's what we expect that market will continue to do.

Oscar Bergman
40:09 - 40:49

If you look at what Jan has done in the prior companies, sustaining and building growth, he's doing it while driving a very disciplined organization that enhances EBIT margin and incremental EBIT margin building. And I know we have talked about the COGS. But I think I'd have to go back to that. So maybe it would be a repeating answer on this, but if you look at the gross margin for the past quarters, it's been above 80%. With increasing direct sales in this quarter, I was quite surprised that the EBIT margin was, compared to the previous quarters, significantly lower. Can you provide some more clarity on this? And were there any one-offs here or any changes from opex to cogs and so on?

Jan Wahlström
40:51 - 41:46

Coming back to the answer I gave before, I can maybe provide some more detail to it. No. So the way that our COGS is set up is that we have, of course, the major part as a variable cost that goes directly to the kit that we sell. But we also have some fixed costs in the COGS part. That part is consistently large every quarter. So when we have a quarter like Q3 with lower sales than other quarters. That portion becomes more significant in that context. That's why you see Q3 last year and Q3 this year having lower margins than other quarters. Looking at the kit pricing and the COGS associated with the products we sell, we do not see any deviation in Q3 compared to previous quarters.

Oscar Bergman
41:47 - 42:15

Coming back to the answer I gave before, I can maybe provide some more detail. And then I've seen some examples before of new CEOs coming in and looking at their financial targets and making adjustments to them. It seems like you stated in the CEO's report that it will require some extensive work to reach the financial targets. What's your confidence level on delivering on these for next year?

Jan Wahlström
42:16 - 42:40

I think that a lot of good work has already been done this year, particularly at the beginning, with the reorganization. There's been some good work also in the second and third quarters moving us in the right direction. And I do believe we have strong growth. Reaching the 20% target is a tough challenge. And I wrote that in the CEO letter. But that is our target. And that's what we're moving towards to reach for next year.

Oscar Bergman
42:42 - 43:18

All right. Returning to the previous answer I provided, I can offer some additional insights. And just a final question on the cash position. And I suspect Sabina will be very concise in this answer as well. But I mean, you burned around, I think, the free cash flow was around 18 million. Negative. If we suppose that you burn this amount consistently, the cash will last roughly five quarters. Do you have any comments on investments, particularly going forward? Is there anything here that is expected to go down?

Jan Wahlström
43:20 - 43:57

Looking at the investments, as you know, we made significant investments when moving to our new building, incorporating all the different systems involved. After that, our main investment is into our R&D, and that is clearly stated in the report. Apart from that, we're not looking at any specific investments going forward. But we're looking at continuing to grow the company, continuing to improve our profitability, and hence continuously progressing towards a positive cash flow. Sabina. Looking at the investments, as you know, I can start there so I can fill in that we did a lot of investments when moving to our new building with all the different systems that we had and so on.

Sabina Berlin
43:57 - 44:39

And I can add also that regarding the cash position, it is one of my most important tasks as CFO, and I do feel comfortable with the trajectories that I'm building. And you have seen a change in both cash flow and in the numbers that we present over the past years. We do see a comfortable path forward that will not continue to drop at the same speed that we have right now.

Oscar Bergman
44:41 - 44:48

Looking at the investments, as you know, I can start there so I can fill in that we did a lot of investments when moving to our new building with all the different systems that we had, and so on. All right. Well, thank you very much. I look forward to talking to you again after the Q4 report.

Jan Wahlström
44:49 - 44:50

Looking at the investments, as you know, I can start there, I can mention that we made significant investments when moving to our new building with all the different systems that we had, and so on. Looking at the investments, as you know, I can start there by saying that we made significant investments when moving to our new building with all the different systems that we had and so on.

Operator
44:53 - 44:57

The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
45:00 - 45:17

Thank you very much. A few additional questions on my end. In Q2, you talked about customer growth in volume in the mid-teens up until Q2.

Theis Kipling
45:18 - 45:39

So we are continuing along that line. So we continue to grow. The number of customers, as I mentioned, stemming from changes made this year on how we generate leads, has created a lot more efficiency in bringing in new customers. And that's what we are seeing across markets, including in Italy, actually.

Ulrich Trattner
45:42 - 46:17

And this might be more addressed to Jan or overall strategy. You have quite an extensive portfolio of tests, and registration is very expensive, especially since the majority of your tests are either IVDR classified or implied to be IVDR classified. So is there any strategic decision here going forward to double down on certain focus areas to cut down costs or anything related to that?

Jan Wahlström
46:18 - 47:05

I think that what we're doing is focusing more on the transplant products and the hereditary side, rather than the oncology side. That's what we've communicated before. And that's still what we do. We are looking at every single new project on what to move to IVDR. But we do see that as a competitive advantage to move in that direction. So, it is a priority for us. But we do that, of course, ensuring that we don't add too much cost and don't do it on products where we don't see the volume. At the same time as we're doing this, we are looking at discontinued products where we don't see that they add volume and where the cost to move to IVDR would be too high.

Ulrich Trattner
47:08 - 47:36

Okay, great. And on capitalized R&D or net capitalized R&D. It is still fairly high. And we have seen a few products here being approved recently, the genomic blood typing and HLA Loss. Are we to expect continued high capitalized R&D? And if high, what type of products are you then planning to move to market here within the next 6 to 12 months?

Jan Wahlström
47:39 - 47:59

We will continue to invest in our product pipeline and maintain our focus on these two areas. I talked about hereditary diseases and transplant products. Exactly which products are something that we cannot comment on here. But we will continue in that direction and we will continue to invest in our R&D pipeline going forward.

Theis Kipling
48:00 - 48:24

Maybe just a side comment, check our Capital Markets Day presentation, because there we actually gave quite some visibility to the underlying pipeline development and advancements we are working on, which are also part of some of those expansion expenses that you're seeing being capitalized. From my point of view, I'm very excited about getting some of those innovations out.

Ulrich Trattner
48:26 - 48:31

Okay, great. Thank you very much. And that was all the questions on my end. Thank you.

Operator
48:37 - 48:56

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Jan Wahlström
48:59 - 49:09

Again, thank you everyone for joining our call today. We certainly feel very good momentum and energy in the company today with many exciting opportunities ahead of us. So thank you all for listening.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…